Relapses of MALT lymphoma may be late and lifelong observation may be required. [9] Investigations General assessment: FBC, renal function tests, electrolytes, LFTs. Phenotyping of circulating lymphocytes, bone marrow lymphocytes or biopsy specimens. Imaging studies for disease staging:
Barium contrast studies of the upper and lower gastrointestinal tract. CT scan and MRI scan.
Endoscopy. Bone marrow aspiration.
Management
Management is different for gastric and non-gastric MALT lymphomas.
Treatment with a proton pump inhibitor (PPI) and antibiotics to eradicate H. pylori is the main treatment for most gastric MALT lymphomas, which are often low-grade and remain localised for several years. Treatment with chemotherapy, surgery or radiotherapy has not been demonstrated to be superior to antibiotic treatment. Treatments for non-gastric MALT lymphomas include radiotherapy, chemotherapy, monoclonal antibodies and surgery. Rituximab alone or in combination with chemotherapy is reported to provide high response rates and has been advocated for those with disseminated or recurrent disease. [10] Surgery has only a limited role in treatment. Surgery for non-gastrointestinal MALT lymphoma is usually restricted to excisional biopsies. Partial or total gastrectomy is associated with considerable morbidity and is rarely necessary.
Specific types of mucosa-associated lymphoid tissue lymphoma

Gastric MALT lymphoma Associated with: H. pylori infection.
Presenting features: dyspepsia, epigastric discomfort, gastric bleeding. Systemic symptoms (night sweats, weight loss, fever, lethargy) and bone marrow involvement are less common. Most are localised to the stomach at presentation.
Diagnosis: endoscopy and gastric biopsy. There are characteristic histological features.
Treatment:
Eradication of H. pylori with antibiotics and a PPI or H2-receptor antagonist can lead to a complete remission of gastric MALT lymphoma in between 65-70% of cases and is first-line treatment for early-stage disease. [1, 11] If H. pylori status is negative, eradication treatment may not work. Close follow-up using endoscopy is needed after eradication treatment to ensure a complete response. [12] If there is locally-advanced or high-grade disease, chemotherapy, monoclonal antibody treatment with rituximab, or radiotherapy should be added to eradication treatment. Surgery is reserved for refractory disease, as gastric preservation is preferred if possible. Current clinical trials involving these different treatment modalities are underway.
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